Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme/No Pennies -- Ignore unavailable to you. Want to Upgrade?

To: TokyoMex who wrote (8933)	11/6/1998 11:06:00 AM
From: Michael Paul Langley	Respond to of 119973

Possible sympathy play with Gern is VMRX (price $1 3/16 with BV of $.97 and Cash at $.71 per share). May move but float is 43.5 million shares Located in Irvine, California, Nexell Therapeutics, Inc. is a biotechnology company jointly owned by VIMRX Pharmaceuticals Inc. (80% owned) (NASDAQ:VMRX - news) and Baxter Healthcare Corporation, the principal domestic operating subsidiary of Baxter International Inc [NYSE:BAX - news]. Nexell is developing and marketing innovative ex vivo cell therapies for cancer, autoimmune, metabolic and genetic diseases. Nexell's lead products, the Isolex(r) Stem Cell Selection System, is marketed in a number of countries and is currently under review by the FDA in the United States. Additionally, Nexell markets an extensive line of cell therapy preparation, storage and expansion products.